| scholarly article | Q13442814 |
| P50 | author | William P Malachowski | Q51737317 |
| James B DuHadaway | Q89209306 | ||
| P2093 | author name string | Alexander J Muller | |
| George C Prendergast | |||
| Syun-Ru Yeh | |||
| Judith M LaLonde | |||
| Ariel Lewis-Ballester | |||
| Maisha Rahman | |||
| Eesha Sheikh | |||
| Jenny Wai | |||
| Maria Winters | |||
| Shorouk Badir | |||
| P2860 | cites work | Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands | Q42199358 |
| Inactivation of catalase by phenylhydrazine. Formation of a stable aryl-iron heme complex. | Q42260606 | ||
| N-Phenylprotoporphyrin IX formation in the hemoglobin-phenylhydrazine reaction. Evidence for a protein-stabilized iron-phenyl intermediate | Q42263733 | ||
| Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice | Q42709035 | ||
| Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. | Q45976913 | ||
| Expression and purification of recombinant human indoleamine 2, 3-dioxygenase. | Q50511756 | ||
| Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins. | Q51980286 | ||
| The role of ligand efficiency metrics in drug discovery. | Q53297758 | ||
| Reaction of myoglobin with phenylhydrazine: a molecular doorstop. | Q53872053 | ||
| Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins | Q71218521 | ||
| The reaction of phenylhydrazine with microsomal cytochrome P-450. Catalysis of heme modification | Q71596490 | ||
| Halogen bonding: the sigma-hole. Proceedings of "Modeling interactions in biomolecules II", Prague, September 5th-9th, 2005 | Q80155379 | ||
| Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors | Q84957588 | ||
| Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties | Q87986410 | ||
| Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors | Q88100816 | ||
| Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan | Q24328949 | ||
| The maximal affinity of ligands | Q24682680 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Structure validation by Calpha geometry: phi,psi and Cbeta deviation | Q27860657 | ||
| Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase | Q28115622 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 | ||
| Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation | Q29616387 | ||
| Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Heme-Containing Oxygenases | Q34114428 | ||
| Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. | Q34394487 | ||
| Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors | Q34443476 | ||
| Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. | Q34550440 | ||
| Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. | Q34655877 | ||
| Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase | Q34802685 | ||
| Density functional theory study on a missing piece in understanding of heme chemistry: the reaction mechanism for indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase | Q34810537 | ||
| Evidence for a ferryl intermediate in a heme-based dioxygenase. | Q35006504 | ||
| Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1). | Q35050032 | ||
| Force fields for protein simulations | Q35590728 | ||
| Complete reaction mechanism of indoleamine 2,3-dioxygenase as revealed by QM/MM simulations. | Q35832639 | ||
| Marrying immunotherapy with chemotherapy: why say IDO? | Q36258584 | ||
| Indoleamine 2,3-dioxygenase and tumor-induced tolerance | Q36809762 | ||
| Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. | Q37087793 | ||
| The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1 | Q37146296 | ||
| A medicinal chemist's guide to molecular interactions | Q37719514 | ||
| Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012). | Q38132933 | ||
| Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors | Q38477478 | ||
| Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. | Q39344305 | ||
| S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. | Q39670708 | ||
| P304 | page(s) | 564-576 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | European Journal of Medicinal Chemistry | Q3008624 |
| P1476 | title | O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. | |
| P478 | volume | 108 |
| Q91718425 | 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth |
| Q39185463 | Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. |
| Q93371164 | Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase |
| Q92734158 | Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening |
| Q28820959 | Erylusamides: Novel Atypical Glycolipids from Erylus cf. deficiens |
| Q40403393 | Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors |
| Q39398164 | Heme-containing enzymes and inhibitors for tryptophan metabolism |
| Q55333337 | Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form. |
| Q53789346 | Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives. |
| Q89703050 | Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors |
Search more.